Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

BEIJING - US pharmaceutical giant Pfizer's new research and development (R&D) center officially opened at BioPark in the ...

Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

The return on investment in pharma research and development (R&D) has increased from the previous year, with GLP-1 drugs ...

In biopharmaceutical development, clinical trials generate vast amounts of data from various experimental sources and methods ...

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, ...

Deloitte, in a series of annual reports on "Measuring the return from pharmaceutical innovation," in collaboration with other member firms, has provided insights into the state of biopharma R&D ...

The value from R&D comes from products that are still in the ... The report suggests that pharma companies should focus on finding areas of unmet need. The companies should also think more boldly ...